RxDoctor Payments Data

Jacqueline Champlain, MD

Family Medicine · Elgin, TXNPI 1497049209

Payments from drug & device makers

$129,620in general payments, 2019–2025

Across 454 payments — averaging $285.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$115K
  • Sanofi-aventis U.S. LLC$11K
  • Boehringer Ingelheim$472
  • GSK$328
  • Gilead$311
  • Lilly USA, LLC$309
  • plus $2K from 26 others

What the payments were for

  • Consulting fees$8,6747%
  • Speaking & faculty fees$95,60174%
  • Travel & lodging$16,99113%
  • Food & beverage$8,0976%
  • Education$2580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,620 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$18,125
Medicare patients
84
Services billed
292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide121$234,869
JardianceEmpagliflozin150$190,659
OzempicSemaglutide110$173,589
EliquisApixaban87$92,028
JanuviaSitagliptin Phosphate50$62,872
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$61,108
MounjaroTirzepatide28$44,424
EntrestoSacubitril/Valsartan33$31,114
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$29,171
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$20,460
Lantus SolostarInsulin Glargine,hum.Rec.Anlog113$19,786
Breo ElliptaFluticasone/Vilanterol29$18,334
Tresiba Flextouch U-200Insulin Degludec25$16,771
XareltoRivaroxaban26$16,054
RybelsusSemaglutide15$14,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$309$279,293149 claims
Boehringer IngelheimJardiance, Spiriva Respimat$472$198,693161 claims
Novo NordiskOzempic, Rybelsus$115,105$188,220125 claims
PfizerEliquis$102$92,02887 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$328$85,178104 claims
MerckJanuvia$16$62,87250 claims
AstraZenecaFarxiga, Lokelma$161$22,70524 claims
AbbVieLinzess$246$8,90515 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$48$2,414258 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Elgin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →